医学
慢性肝炎
接种疫苗
病毒学
环境卫生
乙型肝炎
中国
疫苗接种政策
免疫学
政治学
病毒
法学
作者
Fuqiang Cui,Lipin Shen,Li Li,Huaqing Wang,Fuzhen Wang,Shengli Bi,Jianhua Liu,Guomin Zhang,Feng Wang,Hui Zheng,Xiaojin Sun,Ning Miao,Zundong Yin,Zijian Feng,Azeem Majeed,Yu Wang
标识
DOI:10.3201/eid2305.161477
摘要
Abstract China’s hepatitis B virus (HBV) prevention policy has been evaluated through nationally representative serologic surveys conducted in 1992 and 2006. We report results of a 2014 serologic survey and reanalysis of the 1992 and 2006 surveys in the context of program policy. The 2014 survey used a 2-stage sample strategy in which townships were selected from 160 longstanding, nationally representative, county-level disease surveillance points, and persons 1–29 years of age were invited to participate. The 2014 sample size was 31,713; the response rate was 83.3%. Compared with the 1992 pre–recombinant vaccine survey, HBV surface antigen prevalence declined 46% by 2006 and by 52% by 2014. Among children <5 years of age, the decline was 97%. China’s HBV prevention program, targeted toward interrupting perinatal transmission, has been highly successful and increasingly effective. However, this progress must be sustained for decades to come, and elimination of HBV transmission will require augmented strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI